February 2, 2012

Dexcom and Tandem Announce CGM Development.

From the News Wire:


SAN DIEGO--(BUSINESS WIRE)-- DexCom, Inc. (NASDAQ:DXCM - News), a leader in continuous glucose monitoring systems, announced today that it has entered into a Development and Commercialization Agreement with Tandem Diabetes Care, Inc. to integrate a future generation of DexCom’s continuous glucose monitoring (CGM) technology with Tandem’s t:slim™ Insulin Delivery System, the first ever touch-screen insulin pump.
Under the terms of the Agreement, Tandem will pay DexCom a technology license fee of $3 million, reimburse DexCom’s development, clinical and regulatory expenses, and upon commercialization of the combined system, Tandem will pay DexCom a royalty of $100 for each CGM-enabled insulin pump sold. 
more here
So that is Animas, Omni Pod, Roche and Tandem all working with Dexcom to integrate DGM into their pumps. I think the Animas agreement is exclusive outside the US (see this post). So all the agreements are nice and all, I hope that we see some products in the marketplace.

1 comment:

Roselady said...

I second your comments. Would be nice to actually see Dexcom integrated with a pump in real life. But, smart of them to partner up with as many companies as possible. Who knows which one the FDA will favor, or who will emerge as the most innovative leader in the pump industry. With all the technology on the horizon, Dexcom wouldn't want to miss the next big pump breakthrough. Run with the winners.